Ear drug delivery to get a boost from launch of hearing loss therapeutics company Decibel

VC firm Third Rock is funding (to the tune of $52 million) and assembling a team focused on fighting hearing loss with drugs, an effort that's sure to push the envelope when it comes to drug delivery and administration within the ear. Decibel Therapeutic's founders include Charles Liberman of Harvard Medical School, who studies the use of neurotrophins to restore synapses. The company promises to "combine recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques." GlaxoSmithKline's ($GSK) venture arm also participated in the Series A round. More from FierceBiotech

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.